Zanubrutinib

Status:
Do Not Prescribe (DNP), Red
Decision Date:
October 2024
 

Comments

RED:

  • NICE TA833 - Zanubrutinib for treating Waldenstrom’s macroglobulinaemia. NHSE commissioned. (Decision date - November 2022)
  • SSC2569 - Zanubrutinib for treating chronic lymphocytic leukaemia. NHSE commissioned. (Decision date: November 2023)
  • NICE TA931 - Zanubrutinib for treating chronic lymphocytic leukaemia. NHSE commissioned (Decision date - December 2023)
  • NICE TA1001 - Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment. NHSE commissioned (Decision date - October 2024)

 DNP:

  • NICE TA978 (Terminated appraisal) - Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (Decision date - June 2024)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app